tbuckley/cabot-search huggingface dataset:
Cardiac Glycosides
Authors: Dale G. Friend
Journal: New England Journal of Medicine (1962)

DoseThe basic rule concerning the therapeutic dosage of the cardiac glycosides was delineated long ago by Withering, who wrote, "Let it be continued until it either acts on the kidneys, the stomach, the pulse, or the bowels; let it be stopped upon the first appearance of any of these effects, and I will maintain the patient will not suffer from its exhibition nor the practitioner be disappointed in any reasonable expectation."It is fundamental that the cardiac glycoside chosen be given in adequate amounts to obtain the desired therapeutic effect or, lacking this, the appearance of minor degrees of . . .
Dealing with alleged fraud in medical research
Authors: L. D. Grouse
Journal: JAMA (1982)

Scientific inquiry is self-correcting; fabricated or erroneous data are exposed when their irreproducibility or inconsistency with established observations is discovered. Nevertheless, medical research misconduct and instances of alleged fraud in research cannot be dismissed simply as aberrations. The medical community cannot be content with detecting their occurrence; research misconduct should be prevented. Philip Majerus, MD, president of the American Society for Clinical Investigation, added a useful perspective to this problem in his recent presidential address to the society.<sup>1</sup>He examined the role of medical journals, national agencies, and individual clinical investigators and laboratories in preventing and in responding to alleged research fraud. Dr Majerus argued that medical journals, since they lack an investigative arm, have a limited capacity to deal with potentially fraudulent research. Still, a useful process of scientific scrutiny does take place in peer review. Review may reveal possible inconsistencies or suspicious aspects of a report that
THE ALLEGED BIOLOGIC RADIOACTIVITY OF POTASSIUM SALTS
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAAD Case Reports Article List
Authors: Isabella Doche, Maria Hordinsky, George Wilcox, Neusa Valente, Ricardo Romiti, Margit Juh Asz, Daniel Maman, Joel Levin, Ellen Marmur, Hector Morales-Moreno, Tarsila Montenegro-Damaso, Yeray Peñate, Cassandra Chaptini, Genevieve Casey, Adam Harris, Dedee Murrell, Lynne Gordon, John Evans, J Jensen, Naveed Sami, Angiolymphoid Hyperplasia, Abdulqader Alaidarous, Xavier Bouissou, Juliette Mazereeuw-Hautier, Cristina Bulai-Livideanu, Laurence Lamant, Paul Carle, Hermosura Prurigo, Jae Almazan, Jung Yeon, Matthew Gordon, Jason Sluzevich, Anokhi Jambusaria-Pahlajani, Arjun Dupati, Robert Egbers, Yolanda Helfrich, Jeff Donovan, Oriana Cohen, Sheel Sharma
Journal: Journal of the American Academy of Dermatology (2015)
Christmas Depression
Authors: James Randolph Hillard
Journal: JAMA (1982)

IS CHRISTMAS hazardous to your mental health? A widespread popular belief says that it is. In fact, a notable proportion of what the general public reads about depressive illness concerns depression at Christmas. The<i>Reader's Guide to Periodical Literature</i>, a standard index of 170 widely circulated popular publications, lists 147 articles on "depression, mental" during the last ten years and 21 deal with the "Christmas depression syndrome." The articles have titles like "Christmas Depression and How to Deal With It," "Beat Those Holiday Blues," and "Holidays Got You Down?" They usually include some "case reports," some comments by a psychiatrist, and some helpful hints on how to avoid depression. Newspapers, radio, and television repeat the same general pattern. But what does the medical literature tell us about this much publicized syndrome? <h3>Professional Literature</h3> The relevant professional literature, almost all of it from the United States, contains articles of two types:
Clinical Inertia
Authors: Lawrence S. Phillips, William T. Branch, Curtiss B. Cook, Joyce P. Doyle, Imad M. El-Kebbi, Daniel L. Gallina, Christopher D. Miller, David C. Ziemer, Catherine S. Barnes
Journal: Annals of Internal Medicine (2001)

Medicine has traditionally focused on relieving patient symptoms. However, in developed countries, maintaining good health increasingly involves management of such problems as hypertension, dyslipidemia, and diabetes, which often have no symptoms. Moreover, abnormal blood pressure, lipid, and glucose values are generally sufficient to warrant treatment without further diagnostic maneuvers. Limitations in managing such problems are often due to clinical inertia—failure of health care providers to initiate or intensify therapy when indicated. Clinical inertia is due to at least three problems: overestimation of care provided; use of "soft" reasons to avoid intensification of therapy; and lack of education, training, and practice organization aimed at achieving therapeutic goals. Strategies to overcome clinical inertia must focus on medical students, residents, and practicing physicians. Revised education programs should lead to assimilation of three concepts: the benefits of treating to therapeutic targets, the practical complexity of treating to target for different disorders, and the need to structure routine practice to facilitate effective management of disorders for which resolution of patient symptoms is not sufficient to guide care. Physicians will need to build into their practice a system of reminders and performance feedback to ensure necessary care.
<i>Circulation</i> : Clinical Summaries
Journal: Circulation (2011)

This article describes the frequent (30% of patients) presence of sizable mobile thrombus on pacemaker and defibrillator leads identified with careful intracardiac echocardiographic assessment during ablation procedures for atrial fibrillation and ventricular tachycardia.These thrombi were more frequently seen on the atrial portion of the leads.Prior use of oral anticoagulants or antiplatelet agents, the number and age of leads, and presence of a superior vena cava coil were not specifically associated with lead thrombi during the procedure.The group with thrombus had a higher pulmonary artery pressure, suggesting the possibility that patients with lead thrombi may have subclinical pulmonary emboli elevating the pressure and/or that higher pulmonary artery pressure predisposes to thrombus formation in right-sided cardiac chambers.Further study is warranted to identify hematologic or other clinical factors that may increase patients' risk of forming device lead thrombi and to assess the potential clinical impact of these thrombi.See p 772.
Partial splenic embolization for the treatment of hypersplenism in cirrhosis
Authors: B Sangro
Journal: Hepatology (1993)

Hypersplenism is of great relevance in the management of cirrhosis because of the widespread use of myelodepressant drugs such as interferon or antineoplastic agents. Because no standard therapy exists for this complication, we have evaluated the efficacy and risks of splenic embolization in the treatment of hypersplenism in cirrhosis. Partial splenic embolization was performed in 40 consecutive patients with the following indications: 25 patients with active viral cirrhosis before interferon therapy, 8 patients with unresectable hepatocellular carcinoma before antineoplastic chemotherapy and 7 patients with thrombocytopenia associated with spontaneous bleeding events, with high risk of central nervous system hemorrhage or facing major surgery. After selective catheterization of the splenic artery, partial splenic embolization was performed by means of repeated injections of gelatin sponge until a 40% to 60% reduction in the splenic blood flow was achieved. After partial splenic embolization a significant and sustained increase in platelet and white blood cell count was observed during the follow-up period (mean = 13.9 ± 2.2 mo; range = 1 to 36 mo). The goal of partial splenic embolization was achieved in all but two patients in whom a dose reduction of interferon was needed. Hypersplenism relapsed in only seven patients, and all of them exhibited an embolization of less than 50% of the splenic mass. Postembolization syndrome was the main side effect, but no life-threatening complications were detected. In conclusion, partial splenic embolization is a safe and effective therapy of hypersplenism in cirrhosis. (HEPATOLOGY 1993;18:309–314).
Recovery of Aerosolized Bacteria from Humans: III. Recovery from Nasal Mucus
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Diagnostic Doubts of Dr. Cabot-Reply
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cysticercosis in Los Angeles County
Authors: F. O. Richards
Journal: JAMA (1985)

Four hundred ninety-seven patients were identified as having been treated for cysticercosis at four hospitals in Los Angeles during the 11-year period 1973 through 1983. Eleven deaths were recorded. Over 90% of these patients were Hispanics in productive age groups; the majority were Mexican by nationality. Hospitalizations were generally short, and readmissions for recurrence of symptoms or complications of therapy occurred in only 14% of patients. Cysticercosis was diagnosed in 12 US citizens who had no history of travel to countries considered traditionally endemic for<i>Taenia solium</i>taeniasis/cysticercosis. A dramatic rise in numbers of cases was observed after 1977, appearing to plateau at approximately 80 cases per year in 1981. The increase in cases beginning in 1977 coincided with the introduction of the computed tomographic scan. (<i>JAMA</i>1985;254:3444-3448)
Radiation Therapy
Authors: George W. Dean
Journal: JAMA (1966)

<h3>To the Editor:—</h3> I hasten to express complete disapproval of the answer concerning radiation therapy for lymphoid tissue in the eustachian tube (<b>197</b>:829, 1966) in which it is said, "Under unusual circumstances, radiation therapy is still justifiable." Several articles have appeared in the literature reporting on the frequent subsequent development of malignant tumors in children who have received this very form of treatment. In my practice I have had two children with cancer of the thyroid who have had radiation therapy for this very condition. One died of the disease; in the other, apparently successful removal was accomplished. My opinion is that this form of treatment should be heartily condemned and, indeed, I believe it would be difficult to find a radiotherapist who would administer it.
Retreatment with bendamustine in patients with relapsed/refractory indolent B-cell lymphoma and mantle cell lymphoma
Authors: Toshiki Yamada, Yuhei Shibata, Nobuhiko Nakamura, Jun-ichi Kitagawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Takeshi Hara, Hisashi Tsurumi
Journal: Annals of Oncology (2016)
Skeletal Muscle Is a Primary Target of SOD1G93A-Mediated Toxicity
Authors: Gabriella Dobrowolny, Michela Aucello, Emanuele Rizzuto, Sara Beccafico, Cristina Mammucari, Simona Boncompagni, Silvia Belia, Francesca Wannenes, Carmine Nicoletti, Zaccaria Del Prete, Nadia Rosenthal, Mario Molinaro, Feliciano Protasi, Giorgio Fanò, Marco Sandri, Antonio Musarò
Journal: Cell Metabolism (2009)
Diagnosis of focal hepatic lesions. Combined radioisotope and ultrasound techniques
Authors: J. H. Pritchard
Journal: JAMA (1974)

The detection of space-occupying lesions by routine radiocolloid liver scans is well established. However, a wide variety of pathological processes produce the same scan changes. Gallium 67 concentrates in tissues affected with many neoplastic and inflammatory diseases. Ultrasound B scanning accurately differentiates cystic lesions from those composed of solid tissue. These modalities are complementary and, in combination, can increase the diagnostic specificity of focal hepatic lesions. (<i>JAMA</i>229:1463-1465, 1974)
Phase I trial of thalidomide and capecitabine for treatment of metastatic colorectal cancer
Authors: M. J. Goldstein, J. C. Leighton, A. Chapman, M. Carberry, E. P. Mitchell
Journal: Journal of Clinical Oncology (2005)

3687 Background: Survival of patients with metastatic colorectal cancer (CRC) has increased with the advent of new chemotherapeutic and biologic agents. Yet, there remains a need for more effective third- and fourth-line chemotherapy. Thalidomide (Thal) has angiogenic and immunomodulatory properties and antitumor effects have been consistently demonstrated in pts with multiple myeloma and occasionally in pts with advance solid tumors. Capecitabine (Cape) has demonstrated efficacy as a single agent and in combination therapy in pts with metastatic CRC. We conducted a phase I study of Thal/Cape in pts with refractory metastatic CRC previously treated with irinotecan, oxaliplatin and fluoropyrimidines. Methods: Pts with stage IV CRC who had received two or more prior chemotherapy regimens were eligible. Treatment consisted of Cape at 1500 mg/m2 po daily for 14 days every three weeks with dose levels increasing to 2500mg/m2; Thal dosing was initially 100 mg with escalations individually to 400 mg per day. Toxicity rates, response and overall survival were analyzed. Results: Twenty eligible pts were enrolled; median age= 58 (21–80); M/F=11/9; ECOG PS 0/1/2=3/15/2. The median number of Thal/Cape cycles administered was 3.3 (range 1–9). Treatment was well tolerated; grade 3–4 non-hematologic toxicities included somnolence/syncope (20%), fatigue (20%), constipation (10%), diarrhea (10%), infections (10%) and neuropathy, thrombosis, hypoglycemia, nausea/vomiting each occurred in 5% of pts; grade 3–4 hematological toxicities anemia (15%), neutropenia (5%), prolonged prothrombin time (15%), increased LFTs (10%). Grade 3–4 hand-foot syndrome occurred in 1 pt (5%). There were no radiographic responses, but 6 pts achieved a decline in CEA of 50% or greater and 6 pts achieved stable disease. Conclusion: This study continues at the Cape dose level of 2000mg/m2 per day. The combination of Thal/Cape was well tolerated in this patient population. Despite the lack of radiographic responses, the rate and duration of disease stabilization observed in this heavily pretreated pt population suggest that this regimen may offer some benefit. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene, Roche
Internal fixation by the Ender method
Authors: R. D. Corzatt
Journal: JAMA (1978)

A new method for the intramedullary fixation of trochanteric fractures with prebent, 4.5-mm, round, semielastic nails has theoretical advantages over use of nail-plate devices. Use of the method in 25 patients suggests that it is mechanically sound, relatively easy to learn, and easier for the patient to tolerate. Operating room time is reduced and blood replacement was not necessary. No infections were encountered, and all patients who were ambulatory preoperatively remained ambulatory postoperatively. (<i>JAMA</i>240:1366-1367, 1978)
Abstract 582: Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage, and is associated with inhibition of estrogen-induced breast cancer
Authors: Bhupendra Singh, Hari K. Bhat
Journal: Cancer Research (2012)

Abstract Epidemiological data and studies in rodent models strongly support the role of estrogens in the development of breast cancers. Oxidant stress has been implicated in this carcinogenic process. We have recently demonstrated that antioxidants vitamin C or butylated hydroxyanisole (BHA) severely inhibit 17β-estradiol (E2)-induced breast tumor development in female ACI rats. The objective of the present study was to characterize the mechanism of antioxidant-mediated prevention of breast cancer. Female ACI rats were treated with E2; vitamin C; vitamin C + E2; BHA; and BHA + E2 for up to 8 months. mRNA and protein levels of superoxide dismutase 3 (SOD3) were suppressed in E2-exposed mammary tissues and in mammary tumors of rats treated with E2. This suppression was overcome by co-treatment of rats with E2 and vitamin C or BHA. 8-Hydroxydeoxyguanosine (8-OHdG) levels determined as a marker of oxidative DNA damage were higher in E2-exposed mammary tissues and in mammary tumors compared to age-matched controls. Vitamin C or BHA treatment significantly decreased E2-mediated increase in 8-OHdG levels in the mammary tissues and in MCF-10A cells. Increased nuclear translocation of SOD3 was demonstrated in vitamin C-treated mammary tissues and in MCF-10A cells. Increased DNA damage was detected after silencing SOD3. Our studies suggest that SOD3 provides protection against nuclear DNA damage. Our studies further demonstrate that SOD3 but not SOD2 and SOD1 is induced by antioxidants and is regulated through NRF2. SOD3 may thus be an important gene in defense against oxidant stress and in the prevention of estrogen-mediated breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 582. doi:1538-7445.AM2012-582
BUSINESS.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The deep clavicular rhomboid fossa. Clinical significance and incidence in 10,000 routine chest photofluorograms
Authors: I. A. Shauffer
Journal: JAMA (1966)

IN THE SHORT period of three weeks, we have encountered three cases in which a deep rhomboid fossa of the clavicle was noted roentgenographically. The rhomboid fossa is familiar to radiologists and consists of a roughened area along the lower surface of the medial end of the clavicle which serves as an attachment for the costoclavicular ligament. The latter binds the clavicle to the first rib.<sup>1</sup>Our interest lies in persons in whom the fossa is exaggerated so that the roentgen appearance is that of a crescentic defect which is delineated from the remainder of the clavicle by a band of increased density. Pendergrass and Hodes<sup>2</sup>wrote a comprehensive report on the subject in 1937. Several others<sup>3-7</sup>have written on the subject subsequently. In 1959, Perry et al<sup>8</sup>recorded a case of a pathologic fracture of the clavicle following biopsy of the rhomboid fossa. It was
Death Certificate Completion by Physicians
Authors: Randy Hanzlick
Journal: JAMA (1996)

<h3>To the Editor.</h3> —Drs Messite and Stellman<sup>1</sup>conclude that training in death certificate completion should be part of physician training but usually is not. Similar to their pilot study results, a recent survey of 198 physician medical examiners showed that only 13% received death certificate training in medical school and only 29% received such training during residency (National Association of Medical Examiners interim meeting, Nashville, Tenn, February 1996). However, training should probably include the targeting of selected groups of physicians because many physicians sign few or no death certificates.<sup>2</sup>The following suggestions include acrossthe-board and targeted educational measures. 1. The Association of American Medical Colleges could recommend that all medical schools provide students with (or require students to obtain) readily available instruction manuals on death certification.<sup>3,4</sup> 2. The United States Medical Licensure Examination and other medical school examinations could routinely include questions on death certification. 3. The Accreditation Council on Graduate